Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Stock Information for Spectrum Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Spectrum Pharmaceuticals Inc.

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Coherus Oncology to Participate in Upcoming Investor Conferences
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.